Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Chief Operating Officer | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phathom Pharmaceuticals, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 312,590 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 79,200 · Balance 312,590 F1: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2035-02-26 | Direct | 55,000 |
Reported balance
After 2025-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-27 · Grant · Acquired 55,000 · Balance 55,000 F2: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 3,578.93 |
Reported balance
Holding disclosure · report date 2025-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,578.93 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 785,700 |
Reported balance
Holding disclosure · report date 2025-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 785,700 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2020 Filed Jan 5, 2021 19:17 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 7,614 | $33.93 | $258,367.38 |
DisclosureSEC source: 0001209191-21-001622 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 825,654 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $34.39. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2020 Filed Jan 5, 2021 19:17 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,932 | $33.02 | $162,841.82 |
DisclosureSEC source: 0001209191-21-001622 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 833,268 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.50. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.